Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury

Neuren Pharmaceuticals chief executive Jon Pilcher says the Kiwi firm is in a privileged position. (Image: Neuren Pharmaceuticals)

Rebecca Stevenson

Thu, 08 May 2025

Neuren Pharmaceuticals' boss Jon Pilcher says he was punching the air after leaving a recent successful meeting with the US Food and Drug Administration.Neuren, a local company which develops treatments for neurological disorders including Rett syndrome, has been cleared to begin phase-three trials for the drug NNZ-2591 to treat Phelan-McDermid syndrome. It will be the first-ever phase-three trial in children with the rare genetic condition.The disorders Neuren targets for treatment with its drugs are often debilitating and can ha...

Subscribe to BusinessDesk

Stay informed on business, government and financial developments across New Zealand.

Deeply researched, twice-edited and fact-checked news
Annual subscribers also receive a complimentary subscription to The Wall Street Journal
Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers

You can cancel anytime with two clicks, an email or a phone call.
Find out more.

We are serious about journalism.

Already a Subscriber ? Sign in here.

Name {{ registerForm.errors.get('name') }}

Email address {{ registerForm.errors.get('email') }}

Phone Number {{ registerForm.errors.get('phone') }}

Job Title {{ registerForm.errors.get('title') }}

Password Minimum password length of 8 characters.
Require at least one upper and lowercase, numeric, and special character. {{ registerForm.errors.get('password') }}

Repeat password {{ registerForm.errors.get('password_confirmation') }}

We had trouble validating your card. It's possible your card provider is preventing us from charging the card. Please contact your card provider or customer support.

Credit Card

Cardholder's name

{{ __(plans[index].name) | capitalize }} {{ plans[index].attributes.old_price | currency }} {{ plans[index].price | currency }}

All subscriptions auto renew but are easy to cancel.

I Accept The Terms Of Service

{{ registerForm.errors.get('terms') }}

Tax: {{ taxAmount(selectedPlan) | currency }}

Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}

Energy

Contact secures gas deal with Greymouth

The agreement is for 7 petajoules a year.

Ian Llewellyn 12:30pm

The Quiz Free

QuiznessDesk, Friday, July 4

Take a break and try our quiz.

The Quizmaster 9:15am

Finance

JPMorgan is revamping Its bank for the superrich

There is a minimum required balance of US$10 million.

The Wall Street Journal 9:00am

JPMorgan is revamping Its bank for the superrich

Sponsored

Tough conversations ahead as cost of living drives employee requests for pay rises

Rising living costs put pressure on both workers and employers.

Moneyfit

Sponsored

Why corporate giving matters

Dave Letele and Z provide support where urgent need is overlooked.

Z Energy

More Markets

Markets

Vital board backs Tait takeover

Vital’s board has unanimously recommended that shareholders and option holders accept a full takeover offer from Tait Communications, despite their view that it undervalues the company.In May, Vital shares rallied after it disclosed that Tait, a Christchurch-based critical commun...

Gregor Thompson 9:45am